International Journal of Hematology

, Volume 96, Issue 2, pp 247–253 | Cite as

Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan

  • Mihoko Yotsumoto
  • Shotaro Hagiwara
  • Atsushi Ajisawa
  • Junko Tanuma
  • Tomoko Uehira
  • Hirokazu Nagai
  • Yuko Fujikawa
  • Shunichi Maeda
  • Kiyoshi Kitano
  • Nobuyoshi Arima
  • Kenji Uno
  • Toshiki Iwai
  • Igen Hongo
  • Yasunori Ota
  • Katsuyuki Fukutake
  • Seiji Okada
Original Article

Abstract

The incidence of Hodgkin lymphoma (HL) is paradoxically increasing in the combination anti-retroviral therapy (cART) era. However, there has been no nationwide survey of human immunodeficiency virus (HIV)-associated HL (HIV-HL) in Japan. We retrospectively examined the clinical characteristics and outcomes of 19 newly diagnosed HIV-HL patients at 11 HIV/AIDS and hematology regional hospitals in Japan between 1991 and 2010. At the time of HL diagnosis, 79 % of patients were receiving cART. All the patients, but one received HL diagnoses in the cART era. The median CD4+ cell count at HIV-HL diagnosis was 169/μl. Mixed-cellularity classical Hodgkin lymphoma was the most common subtype occurring in 68 % of the patients; 89 % of the patients were positive for Epstein–Barr virus. Of these 19 patients, 84 % were in advanced stages, with bone marrow involvement observed in 47 % of the patients; 58 % had extranodal sites. All the treated patients were given cART concurrent with HL therapy. The complete remission rate of the treated patients was 87 %. The median OS of the entire cohort was 17 months. These results suggest that the characteristics of HIV-HL in Japan are more aggressive than those of non-HIV-associated HL in Japan, but standard chemotherapy is effective and feasible.

Keywords

Hodgkin lymphoma HIV infection ABVD Antiretroviral therapy EBV 

Notes

Acknowledgments

We are indebted to Mr. Roderick J. Turner, Associate Professor Edward F. Barroga and Professor J. Patrick Barron, Chairman of the Department of International Medical Communications of Tokyo Medical University, for their editorial review of the English manuscript.

Conflict of interest

This study was supported in part by a Health and Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare of Japan (grant number: H22-AIDS-I-002).

References

  1. 1.
    Noy A. Update on HIV lymphoma. Curr Oncol Rep. 2007;9(5):384–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Carbone A, Gloghini A, Larocca LM, Antinori A, Falini B, Tirelli U, Dalla-Favera R, Gaidano G. Human immunodeficiency virus-associated Hodgkin’s disease derives from post-germinal center B cells. Blood. 1999;93(7):2319–26.PubMedGoogle Scholar
  3. 3.
    Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc. 2011;14:16.PubMedCrossRefGoogle Scholar
  6. 6.
    Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth JC, Rockstroh J, Mosthaf F, Horst HA, Brodt HR. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004;125(4):455–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Nguyen ML, Farrell KJ, Gunthel CJ. Non-AIDS-defining malignancies in patients with HIV in the HAART era. Curr Infect Dis Rep. 2010;12(1):46–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Spina M, Carbone A, Gloghini A, Serraino D, Berretta M, Tirelli U. Hodgkin’s disease in patients with HIV infection. Adv Hematol. 2011, pii:402682 [Epub ahead of print].Google Scholar
  10. 10.
    Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, Lopez-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007;92(2):191–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, Mena M, Antinori A, Ammassari A, Talamini R, Vaccher E, di Gennaro G, Tirelli U. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100(6):1984–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Nagai H, Iwasaki N, Odawara T, Okada S. Actual status of AIDS-related lymphoma management in Japan. Int J Hematol. 2008;87(4):442–3.PubMedCrossRefGoogle Scholar
  13. 13.
    The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000; 50(9):696–702.Google Scholar
  14. 14.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: Cancer J Clin. 2011; 61(4):212–36.Google Scholar
  15. 15.
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–14.PubMedCrossRefGoogle Scholar
  16. 16.
    Serraino D, Boschini A, Carrieri P, Pradier C, Dorrucci M, Dal Maso L, Ballarini P, Pezzotti P, Smacchia C, Pesce A, Ippolito G, Franceschi S, Rezza G. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS. 2000;14(5):553–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Franceschi S, Dal Maso L, Pezzotti P, Polesel J, Braga C, Piselli P, Serraino D, Tagliabue G, Federico M, Ferretti S, De Lisi V, La Rosa F, Conti E, Budroni M, Vicario G, Piffer S, Pannelli F, Giacomin A, Bellu F, Tumino R, Fusco M, Rezza G. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr. 2003;34(1):84–90.CrossRefGoogle Scholar
  18. 18.
    Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert JJ. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118(1):44–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin’s disease. Eur J Cancer. 2001;37(10):1276–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). Int J Hematol. 2010;92(5):713–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010;91(3):446–55.PubMedCrossRefGoogle Scholar
  22. 22.
    Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol. 2007;14(3):189–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4(1):3–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Dolcetti R, Boiocchi M. Epstein–Barr virus in the pathogenesis of Hodgkin’s disease. Biomed Pharmacother. 1998;52(1):13–25.PubMedCrossRefGoogle Scholar
  25. 25.
    Flavell KJ, Murray PG. Hodgkin’s disease and the Epstein–Barr virus. Mol Pathol. 2000;53(5):262–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Weiss LM, von Wasielewski R, Delsol G, Poppema S, Stein H. Mixed cellularity classical Hodgkin lymphoma. WHO Classification Tumors of Haematopoetic and Lymphoid Tissues, 4th ed.; 2008. p 331.Google Scholar
  27. 27.
    Hishima T, Oyaizu N, Fujii T, Tachikawa N, Ajisawa A, Negishi M, Nakamura T, Iwamoto A, Hayashi Y, Matsubara D, Sasao Y, Kimura S, Kikuchi Y, Teruya K, Yasuoka A, Oka S, Saito K, Mori S, Funata N, Sata T, Katano H. Decrease in Epstein–Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect. 2006;8(5):1301–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Stein H, Delsol G, Pileris SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma, introduction. WHO Classification Tumors of Haematopoetic and Lymphoid Tissues, 4th Ed.; 2008. p 326.Google Scholar
  29. 29.
    Andrieu JM, Roithmann S, Tourani JM, Levy R, Desablens B, le Maignan C, Gastaut JA, Brice P, Raphael M, Taillan B. Hodgkin’s disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann Oncol. 1993;4(8):635–41.PubMedGoogle Scholar
  30. 30.
    Rubio R. Hodgkin’s disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid. Cancer. 1994;73(9):2400–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24(5):444–50.PubMedCrossRefGoogle Scholar
  32. 32.
    Little RF, Yarchoan R, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2000;12(5):438–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, et al. Epstein–Barr virus as a marker of survival after Hodgkin’s lymphoma: a population-based study. J Clin Oncol. 2005;23(30):7604–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Spina M, Re A, Vaccher E, Gabarre J, Tirelli U. High international prognostic score predicts a worse outcome for patients with Hodgkin’s disease and HIV infection: results of a prospective study with Stanford V regimen. Ann Oncol. 2003;14(4):655–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14(1):59–66.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  • Mihoko Yotsumoto
    • 1
  • Shotaro Hagiwara
    • 2
  • Atsushi Ajisawa
    • 3
  • Junko Tanuma
    • 4
  • Tomoko Uehira
    • 5
  • Hirokazu Nagai
    • 6
  • Yuko Fujikawa
    • 7
  • Shunichi Maeda
    • 8
  • Kiyoshi Kitano
    • 9
  • Nobuyoshi Arima
    • 10
  • Kenji Uno
    • 11
  • Toshiki Iwai
    • 12
  • Igen Hongo
    • 13
  • Yasunori Ota
    • 14
  • Katsuyuki Fukutake
    • 1
  • Seiji Okada
    • 15
  1. 1.Department of Laboratory MedicineTokyo Medical UniversityTokyoJapan
  2. 2.Division of HematologyNational Center for Global Health and MedicineTokyoJapan
  3. 3.Division of Infectious DiseaseTokyo Metropolitan Cancer and Infectious Disease Center, Komagome HospitalTokyoJapan
  4. 4.AIDS Clinical CenterNational Center for Global Health and MedicineTokyoJapan
  5. 5.Department of Infectious DiseaseNational Hospital Organization Osaka National HospitalOsakaJapan
  6. 6.Department of HematologyNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  7. 7.Division of Internal MedicineNagano Prefectural Foundation of Agricultural Cooperative for Health and Welfare, Saku Central HospitalNaganoJapan
  8. 8.Division of ChemotherapyHachinohe City HospitalAomoriJapan
  9. 9.Division of Internal MedicineMatsumoto Medical CenterNaganoJapan
  10. 10.Department of HematologyThe Tazuke Kofukai Medical Research Institute, Kitano HospitalOsakaJapan
  11. 11.Center for Infectious DiseasesNara Medical University HospitalNaraJapan
  12. 12.Division of HematologyKyoto First Red Cross HospitalKyotoJapan
  13. 13.Division of Infectious DiseaseMusashino Red Cross HospitalTokyoJapan
  14. 14.Division of PathologyToranomon HospitalTokyoJapan
  15. 15.Center for AIDS ResearchKumamoto UniversityKumamotoJapan

Personalised recommendations